Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapirosiran in Healthy Adults and Patients with NASH
NCT04565717Phase 1Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of rapirosiran in Nonalcoholic steatohepatitis (NASH) (5 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoints: Frequency of Adverse Events at 12.5 months and Change from Baseline of Liver Hydroxysteroid 17β Dehydrogenase 13 (HSD17B13) Messenger Ribonucleic Acid (mRNA) at 9 months. Started Oct 2020; status: terminated.
02
Drugs
rapirosiran
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04565717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565717.